{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:11:12Z","timestamp":1778584272198,"version":"3.51.4"},"reference-count":43,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"JSPS KAKENHI","award":["24K18715"],"award-info":[{"award-number":["24K18715"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Psychopharmacology"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Modafinil is a wakefulness-promoting agent widely used for narcolepsy and other sleep disorders. Although considered relatively safe, psychotic episodes associated with its use have been reported. However, no systematic review has focused on modafinil-associated psychosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To synthesize and describe the clinical characteristics, diagnostic backgrounds, and treatment outcomes of modafinil-associated psychosis through a systematic review of case reports and series.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Systematic review of published case reports and case series.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources and methods:<\/jats:title>\n                    <jats:p>A systematic literature search was conducted using PubMed and Web of Science. Case reports and series in English describing psychosis related to modafinil or armodafinil use were included. Age, sex, dose, diagnosis, symptoms, treatment, and outcomes were extracted and descriptively analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Twenty-four patients (13 men and 11 women, mean age 37.4\u2009years) from 21 articles were included. The most common symptoms were hallucinations (66.7%) and delusions (58.3%). Median modafinil dose was 250\u2009mg\/day; however, some patients received excessive doses. The diagnoses included narcolepsy (33.3%), schizophrenia (20.8%), and depression (20.8%). Eighteen patients (75.0%) were treated with antipsychotics, and 16 (66.7%) discontinued modafinil. Most patients (70.8%) showed marked improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Modafinil-associated psychosis can develop across wide diagnostic and age ranges, and sometimes even at therapeutic doses. Although the potential risk factors remain unclear, caution should be exercised regarding the drug\u2019s use at high doses, in patients with comorbid psychiatric conditions, and in cases of off-label usage for cognitive enhancement. Long-term follow-up is necessary to monitor outcomes and transition to schizophrenia. Further research is needed to identify the predictive factors and elucidate the underlying neurobiological mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>Not registered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20451253261446554","type":"journal-article","created":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T09:16:12Z","timestamp":1778404572000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Modafinil-associated psychosis: a systematic review of case characteristics and management strategies"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0050-8942","authenticated-orcid":false,"given":"Yutaro","family":"Sato","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Tohoku University Hospital, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Sakuma","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National Hospital Organization Sendai Medical Center, Sendai, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Tomita","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Tohoku University Hospital, Sendai, Japan"},{"name":"Department of Psychiatry, Tohoku University Graduate School of Medicine, Sendai, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,5,10]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.9328"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.4.813-a"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2008.01710.x"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181accefe"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.24869\/psyd.2019.369"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181debcd9"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2014.09.013"},{"key":"e_1_3_4_9_2","article-title":"Modafinil for people with schizophrenia or related disorders","volume":"12","author":"Ortiz-Orendain J","year":"2019","unstructured":"Ortiz-Orendain J, Covarrubias-Castillo SA, Vazquez-Alvarez AO, et al. Modafinil for people with schizophrenia or related disorders. Cochrane Database Syst Rev 2019; 12: CD008661.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001124"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104568"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.3.292"},{"key":"e_1_3_4_13_2","first-page":"26","article-title":"Psychotic relapse in a patient with schizophrenia associated with modafinil therapy","volume":"16","author":"Aggarwal A","year":"2009","unstructured":"Aggarwal A, Garg A, Jiloha RC. Psychotic relapse in a patient with schizophrenia associated with modafinil therapy. Primary Psychiatry 2009; 16: 26\u201327.","journal-title":"Primary Psychiatry"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-219218"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbz102"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.694863"},{"key":"e_1_3_4_17_2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.","journal-title":"BMJ"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2017-110853"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.10.1983"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep25230"},{"key":"e_1_3_4_21_2","first-page":"3732958","article-title":"Modafinil induced psychosis in a patient with bipolar 1 depression","volume":"2018","author":"DiSciullo AA","year":"2018","unstructured":"DiSciullo AA, English CD, Horn WT. Modafinil induced psychosis in a patient with bipolar 1 depression. Case Rep Psychiatry 2018; 2018: 3732958.","journal-title":"Case Rep Psychiatry"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/1039856220936630"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000446"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.5455\/bcp.20111216010146"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318167464d"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/1533317512456450"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31829465b1"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.4040"},{"key":"e_1_3_4_29_2","first-page":"70","article-title":"Narcolepsy-cataplexy and psychosis: a case study","volume":"65","author":"Canellas-Dols F","year":"2017","unstructured":"Canellas-Dols F, Delgado C, Arango-Lopez C, et al. Narcolepsy-cataplexy and psychosis: a case study. Rev Neurol 2017; 65: 70\u201374.","journal-title":"Rev Neurol"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.5152\/npa.2015.7160"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001766"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13300"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.28112"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2021.12.134"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1177\/07067437241245384"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301534"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.351"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199809040-00006"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.3419"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12261"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2018.05.001"},{"key":"e_1_3_4_42_2","article-title":"Treatment of idiopathic hypersomnia with modafinil in an individual at clinical high risk for psychosis: a case report","volume":"4","author":"Sato Y","year":"2025","unstructured":"Sato Y, Sakuma A, Tomita H. Treatment of idiopathic hypersomnia with modafinil in an individual at clinical high risk for psychosis: a case report. PCN Rep 2025; 4: e70115.","journal-title":"PCN Rep"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2024.03.037"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291724001442"}],"container-title":["Therapeutic Advances in Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20451253261446554","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20451253261446554","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20451253261446554","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:20:08Z","timestamp":1778581208000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20451253261446554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":43,"alternative-id":["10.1177\/20451253261446554"],"URL":"https:\/\/doi.org\/10.1177\/20451253261446554","relation":{},"ISSN":["2045-1253","2045-1261"],"issn-type":[{"value":"2045-1253","type":"print"},{"value":"2045-1261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"article-number":"20451253261446554"}}